Preladenant 2 mg tablet
Sponsors
Merck Sharp & Dohme LLC
Conditions
Parkinson Disease
Phase 3
A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)
CompletedNCT01155466
Start: 2010-07-14End: 2012-12-20Updated: 2018-11-06
A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)
TerminatedNCT01155479
Start: 2010-07-06End: 2013-07-16Updated: 2018-11-07